{"commentary":{"count":61,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":51,"youtube":8,"podcast":1,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06158841\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CERVINO","nct_id":"NCT06158841","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cervino-nct06158841. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CERVINO","arms":[{"description":"Participants will receive etentamig as a monotherapy.","label":"Etentamig","type":"EXPERIMENTAL"},{"description":"Participants will receive SAT, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. SAT choices are carfilzomib + dexamethasone (Kd), elotuzumab + pomalidomide + dexamethasone (EloPd), selinexor + bortezomib + dexamethasone (SVd).","label":"Standard Available Therapy (SAT)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":421,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Etentamig","type":"DRUG"},{"name":"Carfilzomib","type":"DRUG"},{"name":"Pomalidomide","type":"DRUG"},{"name":"Elotuzumab","type":"DRUG"},{"name":"Selinexor","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-08-27","lead_sponsor":"AbbVie","official_title":"A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to Approximately 5 Years"},{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to Approximately 5 Years"}],"references":[],"start_date":{"date":"2024-05-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06158841"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cervino-nct06158841"}